Revolutionary Incrementalism: Future-Proofing mRNA Drug Manufacturing
Arguably, one of the greatest challenges facing mRNA therapeutics companies is establishing a well-defined and high-quality drug product manufacturing process—especially when there are few marketed products and limited-to-no dedicated regulatory guidance.
In this panel discussion, John Stubenrauch, Ph.D., Chief Operations Officer at Nutcracker Therapeutics, Hari Pujar, Ph.D., Chief Operating Officer at Tessera, and Anna Rose Welch, Chief Editor at Cell & Gene Collaborative discuss go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare for the clinic and, eventually, the commercial market.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.